Search - tctmd.com

Displaying 301 - 320 of 2724

Sort: Relevancy | Date

News Daily News

Protein-Based Risk Score Shows Potential for Tailored Medicine in Cardiology

Yael L. Maxwell

June 24, 2016

News Daily News

Persistent Low-Flow Aortic Stenosis After TAVR Linked With Higher 1-Year Mortality

Michael O'Riordan

June 23, 2016

News Daily News

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Todd Neale

June 22, 2016

News Daily News

Pharmacists Can Take an Active Role in Lowering CV Risk Factors, Likelihood of Events

Michael H. Wilson

June 21, 2016

News Conference News TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Michael O'Riordan

June 20, 2016

News Daily News

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Yael L. Maxwell

June 20, 2016

News Conference News TVT 2016

Valve Degeneration Data Dearth Spurs Calls for Universal Definitions and Clinical Guidance

Shelley Wood

June 20, 2016

News Conference News TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

Michael O'Riordan

June 18, 2016

Presentation TVT 2016

TVT 1011: High-Risk TAVR in a Failed Freestyle Valve With Low Coronary Height

Presenter: Ashkan Karimi, MD

June 17, 2016

News Conference News TVT 2016

What TAVR Needs Next . . . and What It’s Getting

Shelley Wood

June 17, 2016

Presentation TVT 2016

TVT 1011: High-Risk TAVR in a Failed Freestyle Valve With Low Coronary Height

Presenter: Ashkan Karimi

June 17, 2016

News Conference News TVT 2016

To Intervene or Not to Intervene When the TAVR Patient Has CAD: New Insights

Shelley Wood

June 17, 2016

News Features

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Caitlin E. Cox

June 17, 2016

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

Updates From the UK All-Comer TAVR Study

Presenter: Neil E. Moat

June 16, 2016

Presentation TVT 2016

Updates From SURTAVI in Intermediate-Risk Patients

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients

Presenter: Vinod H. Thourani

June 16, 2016

Presentation TVT 2016

Updates From NOTION: The First All-Comer TAVR Trial

Presenter: Lars Sondergaard

June 16, 2016

Presentation TVT 2016

Highlights From PARTNER 2A in Intermediate-Risk Patients

Presenter: Michael J. Mack

June 16, 2016

Advertisement

Protein-Based Risk Score Shows Potential for Tailored Medicine in Cardiology

Persistent Low-Flow Aortic Stenosis After TAVR Linked With Higher 1-Year Mortality

‘Lower Is Better’ Mantra for LDL Cholesterol Questioned by New Analysis, but Experts Urge Caution

Pharmacists Can Take an Active Role in Lowering CV Risk Factors, Likelihood of Events

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

Prolonged Full-Dose Bivalirudin May Preserve Bleeding Benefit Without Upping Thrombotic Events After STEMI, Meta-Analysis Suggests

Valve Degeneration Data Dearth Spurs Calls for Universal Definitions and Clinical Guidance

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

TVT 1011: High-Risk TAVR in a Failed Freestyle Valve With Low Coronary Height

What TAVR Needs Next . . . and What It’s Getting

TVT 1011: High-Risk TAVR in a Failed Freestyle Valve With Low Coronary Height

To Intervene or Not to Intervene When the TAVR Patient Has CAD: New Insights

Digesting the Valve Degeneration Data: One Month Later, Reactions From TAVR Experts Range From ‘Disturbed’ to Indifferent

Study Design for the PARTNER 3 Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

Updates From the UK All-Comer TAVR Study

Updates From SURTAVI in Intermediate-Risk Patients

Highlights From the SAPIEN 3 Experience in Intermediate-Risk Patients

Updates From NOTION: The First All-Comer TAVR Trial

Highlights From PARTNER 2A in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content